Previous 10 | Next 10 |
2023-12-14 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Ocular Therape...
2023-12-14 05:55:40 ET Related stock stories: Adobe Inc. (ADBE) Q4 2023 Earnings Call Transcript Adobe: The Party Already Ended (Downgrading To Hold) Adobe Just Keeps Rising: How To Prepare For Q4 Earnings Adobe in charts: Creative Cloud revenue climbs 12% fr...
2023-12-13 16:59:17 ET Gainers: Codexis ( CDXS ) +16% . Nubia Brand International ( NUBI ) +13% . E.W. Scripps Company ( SSP ) +5% . WAVE Life Sciences ( WVE ) +5% . Losers: Amtech Systems ( ASYS ) -31% . Mont...
2023-12-13 16:20:24 ET More on Codexis, Danaher, etc. Danaher Corporation (DHR) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Danaher Corporation: A Good Contrarian Bet Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles Go...
REDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins fo...
Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineer...
REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8, 2023, to discuss the growth of RNA interference (RNAi) therapeutics as a modality, the manufacturing l...
2023-12-10 13:04:00 ET More on AbCellera Biologics, Absci, etc. AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Certara, Inc. 2023 Q3 - Results - Earnings Call Prese...
2023-11-29 14:46:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit m...
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA in...
News, Short Squeeze, Breakout and More Instantly...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...
2024-05-30 07:00:11 ET Kristen Kluska from Cantor Fitzgerald issued a price target of $11.00 for CDXS on 2024-05-30 06:15:00. The adjusted price target was set to $11.00. At the time of the announcement, CDXS was trading at $3.19. CDXS currently trades -34.90% versus its...
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York. Management will participate in a f...